LY570310

2 trials

Sponsors

Tibotec BVBA

Conditions

Hepatitis C infection MedDRA version: 9.1 Level: LLT Classification code 10008912 Term: Chronic hepatitis C

Unknown Phase

A Phase IIa randomized, open-label study of telaprevir (VX-950) administered every 12 or every 8 hours in combination with either Peg-IFN alfa2a (Pegasys®) and ribavirin (Copegus®) or Peg-IFN alfa2b (PegIntron®) and ribavirin (Rebetol®) in treatment naïve subjects with chronic genytype 1 hepatitis C infection.

Active, not recruitingEUCTR2007-001044-44-BE

Tibotec BVBAHepatitis C infection MedDRA version: 9.1 Level: LLT Classification code 10008912 Term: Chronic hepatitis C

Start: 2007-08-01Target: 160Updated: 2012-04-18

A Phase IIa randomized, partially blinded trial of telaprevir (VX-950) in treatment-naïve subjects with chronic genotype 2 or 3 hepatitis C infection

Active, not recruitingEUCTR2007-002920-14-GB

Tibotec BVBAHepatitis C infection MedDRA version: 9.1 Level: LLT Classification code 10008912 Term: Chronic hepatitis C

Start: 2007-11-14Target: 48Updated: 2012-03-19